Human Vaccines & Immunotherapeutics (Nov 2021)

Reply letter to “safety of SARS-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance”

  • Rebeca Saborido-Fiaño,
  • Nazareth Martinón-Torres,
  • Vanesa Crujeiras-Martinez,
  • Maria Luz Couce,
  • Rosaura Leis

DOI
https://doi.org/10.1080/21645515.2021.1959149
Journal volume & issue
Vol. 17, no. 11
pp. 4115 – 4116

Abstract

Read online

In the letter, Urro et al. performed a search on the sucrose, fructose and sorbitol content in the approved Sars-Cov-2 vaccines and they concluded that these vaccines can be safely administered in adults affected by Hereditary fructose intolerance. The Pfizer-BioNTech COVID-19 Vaccine is currently approved for use in adolescents ≥ 12 years and the Moderna COVID-19 vaccine is close to approval for use in children over 12 years of age. Furthermore, both vaccines have initiated clinical trials that will include infant as young as 6 months. Therefore, we considerate important to analyze the safely administration of this two vaccines in children with Hereditary fructose intolerance.

Keywords